 BioMarin Pharmaceutical Inc. BMRN , Financial investors could be in for a surprise according to a client note by SVB Leerink analyst Joseph Schwartz. FiercePharma reported that after polling physicians, he concluded the companys dwarfism drug, Voxzogo, could become a billion-dollar seller. 